Low dose product and method for treating diarrhea

Abstract

A method of treating diarrhea in a patient includes administering a dose of 2.0-7.0 mg of cetirizine and 3.0-15.0 mg of famotidine.

What is claimed is: 
     
         1 . A method of treating diarrhea in a patient, comprising:
 administering cetirizine and famotidine, wherein the cetirizine is administered in a dose of 2.0-7.0 mg per day and the famotidine is administered in a dose of 3.0-15.0 mg per day.   
     
     
         2 . The method of  claim 1 , wherein the cetirizine is administered in a dose of 3.0-6.0 mg per day and the famotidine is administered in a dose of 5.0-14.0 mg per day. 
     
     
         3 . The method of  claim 1 , wherein the cetirizine is administered in a dose of 4.5-5.5 mg per day and the famotidine is administered in a dose of 11.0-13.0 mg per day. 
     
     
         4 . The method of  claim 1 , wherein the patient has chronic diarrhea. 
     
     
         5 . The method of  claim 1 , wherein the patient has IBS-D. 
     
     
         6 . The method of  claim 1 , wherein the patient has acute diarrhea. 
     
     
         7 . The method of  claim 1 , wherein the cetirizine and famotidine are administered simultaneously. 
     
     
         8 . The method of  claim 1 , wherein cetirizine and famotidine are administered once per day for at least 2 days. 
     
     
         9 . The method of  claim 1 , wherein the cetirizine and famotidine are administered once per day for at least 7 days. 
     
     
         10 . The method of  claim 1 , wherein the patient does not have mastocytic enterocolitis 
     
     
         11 . A pharmaceutical composition for treating diarrhea, comprising:
 2.0-7.0 mg cetirizine, and   3.0-15.0 mg famotidine.   
     
     
         12 . The composition of  claim 11 , wherein the composition comprises 3.0-6.0 mg cetirizine and 5.0-14.0 mg famotidine. 
     
     
         13 . The composition of  claim 11 , wherein the composition comprises 4.5-5.5 mg cetirizine and 11.0-13.0 mg famotidine. 
     
     
         14 . The composition of  claim 11 , wherein the composition is an oral dosage form. 
     
     
         15 . The composition of  claim 11 , wherein composition comprises a unit dosage form. 
     
     
         16 . The pharmaceutical composition of  claim 11 , wherein the unit dosage form comprises at least one tablet or capsule. 
     
     
         17 . The pharmaceutical composition of  claim 11 , wherein the unit dosage form further comprises sodium, and glucose or a glucose-containing saccharide. 
     
     
         18 . The pharmaceutical composition of  claim 11 , wherein the unit dosage form further comprises an oral rehydration solution. 
     
     
         19 . The pharmaceutical composition of  claim 11 , wherein the oral dosage form comprises a plurality of unit dosage forms. 
     
     
         20 . The pharmaceutical composition of  claim 11 , comprising:
 2.0-3.0 mg cetirizine, and   3.0-5.0 mg famotidine.   
     
     
         21 . A method of treating IBS-D in a patient, comprising: administering cetirizine and famotidine to the patient, wherein the cetirizine is administered in a dose of 2.0-7.0 mg per day and the famotidine is administered in a dose of 3.0-15.0 mg per day. 
     
     
         22 . The method of  claim 1 , wherein the diarrhea is selected from the group consisting of: secretory diarrhea, osmotic diarrhea, inflammatory diarrhea, functional diarrhea, malabsorbtive diarrhea, drug induced diarrhea, food intolerance diarrhea and IBS-D.